Janssen’s Darzalex (daratumumab) Receives Health Canada Approval for the Treatment of Multiple Myeloma

December 23, 2020 Auto Bot daratumumab, DARZALEX, Janssen, multiple myeloma, receives, regulatory, Treatment 0

Shots:

  • The approval is based on P-lll CASSIOPEIA (MMY3006) Study involve the assessing of Darzalex (daratumumab) + bortezomib, thalidomide, and dexamethasone (VTd) for the treatment of patients with multiple myeloma are eligible for (ASCT)
  • Result: The 1EPs of sCR rate post-transplant was significantly higher (29 % vs. 20 %); median follow-up (18.8 mos.); reduction in the risk of disease progression or death (53%)
  • Darzalex is the first CD38-directed mAb approved to treat multiple myeloma. The subcutaneous formulation was approved by Health Canada to treat patients with multiple myeloma in 2020

Click here ­to­ read full press release/ article | Ref: Newswire.CA  | Image: Philadelphia Inquirer

The post Janssen’s Darzalex (daratumumab) Receives Health Canada Approval for the Treatment of Multiple Myeloma first appeared on PharmaShots.